We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Lidco Group Plc | LID | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 11.75 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 11.75 | 11.75 |
| Top Posts |
|---|
Posted at 02/11/2020 16:09 by gbenson1 Interesting buying in and around the offer price, makes me believe investors think a higher/alternative offer is coming! |
Posted at 05/5/2020 12:55 by t0pgrader Notes from Today's Investor PresentationLidco possesses >60% NHS share Primary target market is Edwards (80% US market share) whose technology is inferior in some regards and whose pricing is materially more expensive (x4 per customer) 2018-24 HM industry expected to increase in value from $800m to $1.2b with fater rate of growth in the advanced sector in which Lidco operates Underlying GP margin is 70% from 66% 98% Lidco customer retention rate according to analyst report out today approx 80% of current yr sales already under licence one third of 200 monitors sold since yr end sold with HUP licences. >85% of the 200 are expected to be used going forwards Vs 15% likely to go into stock reserve MS unapologetically emphasised the M&A undervalue of the company with reference to recent industry exit multiples Board not yet decided how best to invest BS cash to accelerate US growth rate Largest single commercial uncertainty is speed of recovery in elective surgery |
Posted at 05/5/2020 12:19 by t0pgrader Comment from Investor PresentationPrimary target market is Edwards (80% US market share) whose technology is inferior in some regards and whose pricing is materially more expensive (x4 per customer) Underlying GP margin up to 70% from 66% 98% Lidco retention rate according to analyst report out today approx 80% of current yr sales already under licence one third of 200 monitors sold since yr end sold with HUP licences. >85% of the 200 are expected to be used going forwards Vs 15% likely to go into stock reserve MS emphasised the M&A undervalue of the company Board not yet decided how best to invest BS cash to accelerate US growth rate Largest single uncertainty is speed of recovery in elective surgery |
Posted at 05/5/2020 11:42 by t0pgrader Comment from Investor PresentationPrimary target market is Edwards (80% US market share) whose technology is inferior in some regards and whose pricing is materially more expensive (x4 per customer) Underlying GP margin up to 70% from 66% 98% Lidco retention rate according to analyst report out today approx 80% of current yr sales already under licence one third of 200 monitors sold since yr end sold with HUP licences. >85% of the 200 are expected to be used going forwards Vs 15% likely to go into stock reserve MS emphasised the M&A undervalue of the company Board not yet decided how best to invest BS cash to accelerate US growth rate The major headwind is the delay in elective surgery |
Posted at 09/4/2020 12:38 by nobbygnome Isn't it funny how buywell wants to question every aspect of ODM but when you ask him a simple question about LID's technology, he goes mute. I think we can all come to the same conclusion about his motives. He is only interested in spreading libellous comments about DEMG and not answering genuine queries about the deficiencies in LID's data.Very sad and if I was a LID investor who has hung on his every word, I would be extremely disappointed. |
Posted at 13/2/2020 12:36 by t0pgrader Same investor group. Details included in the RNS. |
Posted at 18/11/2019 12:15 by 7767 Re Director dealing Why pay over a penny more than they are in the market ??????? |
Posted at 09/11/2019 12:10 by multibagger LiDCO to present at Mello London, 2019LiDCO (AIM: LID), the hemodynamic monitoring company, is pleased to announce that the Company will be attending the Mello London, 2019 investor conference taking place on Tuesday 12th & Wednesday 13th November 2019 to be held at the Clayton Hotel Chiswick, Chiswick High Road, London, W4 5RY. Matt Sassone, Chief Executive Officer of LiDCO, will be presenting to delegates on Tuesday 12th November 2019. For further information on the Mello London conference, please visit the event website hxxps://melloevents. |
Posted at 15/10/2019 17:01 by multibagger Thanks gsbmba99 for your perspective - I haven't got the FinnCap Note but agree that if monitors are not being placed in the USA, that is an issue that the Company needs to try and explain to investors.I gather that at a recent event a figure of reaching 300 HUP monitors in the US was mentioned in this financial year to end Jan 2020. Wonder if there will be the expected traction in China in H2. Edit/Correction: My apologies: 200 HUP monitors in the USA and not 300 in this financial year. |
Posted at 14/10/2019 01:03 by davidosh Just to let shareholders and potential investors in Lidco know that the management team will be exhibiting and presenting on the first day of the two day Mello London investor conference in Chiswick London W4 on Tuesday 12th and Wednesday 13th November and there will be an opportunity to take part in a Q&A at the end of each presentation. These are just a few of the companies taking part...There will also be lots of quality keynote speakers, panel sessions and round table discussions looking at investment strategies & portfolio diversification plus sessions on.... How does a market maker work your share trades? What is undertaken in a company audit? What is hidden on the dark web? & how can retail investors get access to placings? If you would like to join the thousand investors at the event you can gain 30% discount on your ticket by entering the code ADVFN30 when you purchase your ticket. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
